Cytori licensee Kerastem receives conditional FDA approval for alopecia trialCytori Therapeutics announced that Kerastem Technologies, a wholly owned subsidiary of Bimini Technologies, received U.S. FDA conditional Investigational Device Exemption approval to conduct a clinical trial studying the safety and feasibility of its technology for the treatment of female and early male pattern baldness.The phase II study, known as the STYLE trial, follows initial clinical work in Europe and Japan. This clinical experience served as a basis for the FDA IDE submission. The data will be presented in September at the 2015 International Society of Hair Restoration Surgery meeting in Chicago. STYLE is a 70 patient controlled trial that is expected to begin enrollment in late 2015 at up to eight centers within the United States. The primary endpoint is safety and tolerability of the treatment and secondary endpoints include change in hair growth and density. In 2013, Bimini, a private medical technology company, acquired global and exclusive rights to commercialize Cytori Celution Technology for alopecia and hair related indications. Under the commercial agreement, Bimini will be responsible for all key activities including clinical studies, regulatory approvals, and market development. Bimini will acquire Cytori products at agreed upon transfer pricing and pay Cytori a perpetual royalty on sales.